Moderna’s Vaccine Gets Panel Nod In Adolescents, Older Children; Committee Already Eyes Booster

 
• By Sue Sutter

US FDA advisory committee members debate how a third dose, or booster, of the COVID vaccine should fit into the mix of an EUA expansion for the 12-17 and 6-11 groups; Moderna expects to have immunogenicity and safety data on booster doses in both of age groups by mid-July.

Eight ball
When it comes to chasing variants with vaccines, "we're always going to be behind the eight ball," a VRBPAC member said. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers